



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <small>(to be used for all correspondence after initial filing)</small>	Application Number	10/588,602
	Filing Date	August 7, 2006
	First Named Inventor	Quinn Tang
	Art Unit	Not Yet Assigned
	Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	Not Yet Assigned	INTM/019 US

ENCLOSURES <small>(Check all that apply)</small>		
<input type="checkbox"/> Fee Transmittal Form (in duplicate) <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Preliminary Amendment and Response to Notification of Defective Response (in duplicate) <input type="checkbox"/> Assertion of Small Entity Status under 37 C.F.R. § 1.27(c)(1) <input type="checkbox"/> Supplemental Application Data Sheet <input type="checkbox"/> Declaration (executed) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input checked="" type="checkbox"/> Sequence Listing (Computer readable diskette) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. Statement under 37 CFR §§ 1.825(a) and (b); 2. Paper copy of Sequence Listing (54 pages); 3. Copy of Notification of Defective Response, including marked-up Raw Sequence Listing; and 4. Postcard.
Remarks The Director is hereby authorized to charge any fee due, or to credit any overpayment, in connection with this submission to Deposit Account No. 06-1075, Order No. 104825-0019. A duplicate copy of this Transmittal is enclosed herewith.		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	Ropes & Gray LLP		
Signature			
Printed name	Alla Brukman		
Date	July 10, 2008	Reg. No.	61,254


CERTIFICATE OF EXPRESS MAIL TRANSMISSION – Express Mail No.: EM014769592US			
I hereby certify that this correspondence is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to Mail Stop: PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.			
Signature			
Typed or printed name	SARAH SCHLIE	Date	July 10, 2008


This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <small>(to be used for all correspondence after initial filing)</small>	Application Number	10/588,602
	Filing Date	August 7, 2006
	First Named Inventor	Quinn Tang
	Art Unit	Not Yet Assigned
	Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	Not Yet Assigned	INTM/019 US

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form (in duplicate) <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Preliminary Amendment and Response to Notification of Defective Response (in duplicate) <input type="checkbox"/> Assertion of Small Entity Status under 37 C.F.R. § 1.27(c)(1) <input type="checkbox"/> Supplemental Application Data Sheet <input type="checkbox"/> Declaration (executed) <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input checked="" type="checkbox"/> Sequence Listing (Computer readable diskette) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. Statement under 37 CFR §§ 1.825(a) and (b); 2. Paper copy of Sequence Listing (54 pages); 3. Copy of Notification of Defective Response, including marked-up Raw Sequence Listing; and 4. Postcard.
<div style="border: 1px solid black; padding: 2px; display: inline-block;">Remarks</div> The Director is hereby authorized to charge any fee due, or to credit any overpayment, in connection with this submission to Deposit Account No. 06-1075, Order No. 104825-0019. A duplicate copy of this Transmittal is enclosed herewith.		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm Name	Ropes & Gray LLP	
Signature		
Printed name	Alla Brukman	
Date	July 10, 2008	Reg. No. 61,254

CERTIFICATE OF EXPRESS MAIL TRANSMISSION – Express Mail No.: EM014769592US		
I hereby certify that this correspondence is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to Mail Stop: PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.		
Signature		
Typed or printed name	SARAH SCHLIE	Date July 10, 2008

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/588,602	Quinn Tang	INTM/019 US

1473

ROPES & GRAY LLP
PATENT DOCKETING 39/361
1211 AVENUE OF THE AMERICAS
NEW YORK, NY 10036-8704

INTERNATIONAL APPLICATION NO.

PCT/US05/03857

I.A. FILING DATE	PRIORITY DATE
02/07/2005	02/05/2004

CONFIRMATION NO. 7130
371 FORMALITIES LETTER



OC000000030387/15

Date Mailed: 06/10/2008

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- Indication of Small Entity Status
- Priority Document
- Copy of the International Application filed on 08/07/2006
- Copy of the International Search Report filed on 08/07/2006
- Copy of IPE Report filed on 08/07/2006
- Copy of Annexes to the IPER filed on 08/07/2006
- Preliminary Amendments filed on 08/07/2006
- Biochemical Sequence Diskette filed on 06/13/2007
- Oath or Declaration filed on 06/13/2007
- Biochemical Sequence Listing filed on 06/13/2007
- Small Entity Statement filed on 06/13/2007
- U.S. Basic National Fees filed on 08/07/2006
- Priority Documents filed on 08/07/2006
- Paper nucleotide sequence listings filed on 06/13/2007

Applicant's response filed 06/13/2007 is hereby acknowledged. The following requirements set forth in the NOTIFICATION of MISSING REQUIREMENTS mailed 04/13/2007 have not been completed.

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Refer to attachment or PAIR document dated 02-21-2008.

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.
<https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

KAREN R MCLEAN

Telephone: (703) 308-9140 EXT 214

=====

Sequence Listing could not be accepted due to errors.

See attached Validation Report.

If you need help call the Patent Electronic Business Center at (866)
217-9197 (toll free).

Reviewer: Anne Corrigan

Timestamp: [year=2007; month=11; day=27; hr=14; min=13; sec=36; ms=956;
]

=====

Reviewer Comments:

<210> 1

<211> 21

<212> DNA

<213> Mus musculus

<400> 1

aagccgctcct gtgtgccgct g

Please insert a cumulative nucleotide total at the right margin. This
type of error appears globally. FYI: per Sequence Rules, the maximum
number of characters per line (includes white spaces) is 72.

Application No:

10588602

Version No:

1.0

Input Set:

Output Set:

Started: 2007-11-02 19:37:59.191

Finished: 2007-11-02 19:38:05.924

Elapsed: 0 hr(s) 0 min(s) 6 sec(s) 733 ms

Total Warnings: 22

Total Errors: 373

No. of SeqIDs Defined: 374

Actual SeqID Count: 374

Error code	Error Description
E 254	The total number of bases conflicts with running total Input: 0, Calculated : 21 SEQID(1)
E 254	The total number of bases conflicts with running total Input: 0, Calculated : 21 SEQID(2)
E 254	The total number of bases conflicts with running total Input: 0, Calculated : 21 SEQID(3)
E 254	The total number of bases conflicts with running total Input: 0, Calculated : 21 SEQID(4)
E 254	The total number of bases conflicts with running total Input: 0, Calculated : 21 SEQID(5)
E 254	The total number of bases conflicts with running total Input: 0, Calculated : 21 SEQID(6)
W 213	Artificial or Unknown found in <213> in SEQ ID (7)
E 254	The total number of bases conflicts with running total Input: 0, Calculated : 10 SEQID(7)
W 213	Artificial or Unknown found in <213> in SEQ ID (8)
E 254	The total number of bases conflicts with running total Input: 0, Calculated : 15 SEQID(8)
E 254	The total number of bases conflicts with running total Input: 0, Calculated : 21 SEQID(9)
E 254	The total number of bases conflicts with running total Input: 0, Calculated : 21 SEQID(10)
W 213	Artificial or Unknown found in <213> in SEQ ID (11)
E 254	The total number of bases conflicts with running total Input: 0, Calculated : 21 SEQID(11)
W 213	Artificial or Unknown found in <213> in SEQ ID (12)

Input Set:

Output Set:

Started: 2007-11-02 19:37:59.191
Finished: 2007-11-02 19:38:05.924
Elapsed: 0 hr(s) 0 min(s) 6 sec(s) 733 ms
Total Warnings: 22
Total Errors: 373
No. of SeqIDs Defined: 374
Actual SeqID Count: 374

Error code	Error Description
E 254	The total number of bases conflicts with running total Input: 0, Calculated : 21 SEQID(12)
W 213	Artificial or Unknown found in <213> in SEQ ID (13)
E 254	The total number of bases conflicts with running total Input: 0, Calculated : 47 SEQID(13)
W 213	Artificial or Unknown found in <213> in SEQ ID (14)
E 254	The total number of bases conflicts with running total Input: 0, Calculated : 47 SEQID(14)
W 213	Artificial or Unknown found in <213> in SEQ ID (15)
E 254	The total number of bases conflicts with running total Input: 0, Calculated : 47 SEQID(15)
W 213	Artificial or Unknown found in <213> in SEQ ID (16)
E 254	The total number of bases conflicts with running total Input: 0, Calculated : 30 SEQID(16)
W 213	Artificial or Unknown found in <213> in SEQ ID (17)
E 254	The total number of bases conflicts with running total Input: 0, Calculated : 30 SEQID(17)
W 213	Artificial or Unknown found in <213> in SEQ ID (18)
E 254	The total number of bases conflicts with running total Input: 0, Calculated : 30 SEQID(18)
W 213	Artificial or Unknown found in <213> in SEQ ID (19)
E 254	The total number of bases conflicts with running total Input: 0, Calculated : 30 SEQID(19)
W 213	Artificial or Unknown found in <213> in SEQ ID (20)
E 254	The total number of bases conflicts with running total Input: 0, Calculated : 20 SEQID(20) This error has occurred more than 20 times, will not be displayed
W 213	Artificial or Unknown found in <213> in SEQ ID (21)

Input Set:

Output Set:

Started: 2007-11-02 19:37:59.191

Finished: 2007-11-02 19:38:05.924

Elapsed: 0 hr(s) 0 min(s) 6 sec(s) 733 ms

Total Warnings: 22

Total Errors: 373

No. of SeqIDs Defined: 374

Actual SeqID Count: 374

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (22)
W 213	Artificial or Unknown found in <213> in SEQ ID (23)
W 213	Artificial or Unknown found in <213> in SEQ ID (24)
W 213	Artificial or Unknown found in <213> in SEQ ID (25)
W 213	Artificial or Unknown found in <213> in SEQ ID (26)
W 213	Artificial or Unknown found in <213> in SEQ ID (27)
W 213	Artificial or Unknown found in <213> in SEQ ID (28)
	This error has occurred more than 20 times, will not be displayed

SEQUENCE LISTING

<110> TANG, QUINN
LU, PATRICK
XIE, FRANK
WOODLE, MARTIN

<120> RNAI THERAPEUTICS FOR TREATMENT OF EYE
NEOVASCULARIZATION DISEASES

<130> INTM/019 US

<140> 10588602
<141> 2007-11-02

<150> PCT/US05/003857
<151> 2005-02-07

<150> 60/541,775
<151> 2004-02-05

<160> 374

<170> PatentIn Ver. 3.3

<210> 1
<211> 21
<212> DNA
<213> Mus musculus

<400> 1
aagccgtcct gtgtgccgct g

<210> 2
<211> 21
<212> DNA
<213> Mus musculus

<400> 2
aacgatgaag ccctggagtg c

<210> 3
<211> 21
<212> DNA
<213> Mus musculus

<400> 3
aagttaaaag tgctgaact g

<210> 4
<211> 21
<212> DNA
<213> Mus musculus

<400> 4
aagcaggcca gactctcttt c

<210> 5
<211> 21
<212> DNA
<213> Mus musculus

<400> 5
aagctcagca cacagaaaga c

<210> 6
<211> 21
<212> DNA
<213> Mus musculus

<400> 6
aatgcggcgg tggtagacagt a

<210> 7
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 7
tcaacgttga

<210> 8
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 8
gctagacgtt agcgt

<210> 9
<211> 21
<212> DNA
<213> Escherichia coli

<400> 9
aacagttgcg cagcctgaat g

<210> 10
<211> 21
<212> DNA
<213> Escherichia coli

<400> 10
aacttaatcg ccttgacagca c

<210> 11
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 11
aagctatgaa acgatatggg c

<210> 12
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 12
aaccgctgga gagcaactgc a

<210> 13
<211> 47
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
primer

<400> 13
gaacatcgat gacaagctta ggtatcgata caagctgcct cgccttg

<210> 14
<211> 47
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
primer

<400> 14

gaacatcgat gacaagctta ggtatcgata tagattgaag attccgc

<210> 15

<211> 47

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
primer

<400> 15

gaacatcgat gacaagctta ggtatcgata ggtcactgac agaggcg

<210> 16

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
primer

<400> 16

gaacatcgat gacaagctta ggtatcgata

<210> 17

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
primer

<400> 17

gatgtctacc agcgaagcta ctgccgtccg

<210> 18

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
primer

<400> 18

gtcagctgct gggacaccgc ggtcttgctt

<210> 19



<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
primer

<400> 19
ggcgctgcta gctgtcgtc tgtggttctg

<210> 20
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
primer

<400> 20
cctggtcacc agggtgctt

<210> 21
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
primer

<400> 21
ccagccttct ccatggtggt

<210> 22
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
primer

<400> 22
gcgggctgcc tcgcagtc

<210> 23
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
primer

<400> 23
tcaccgcctt ggcttgtcac

<210> 24
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
primer

<400> 24
catcctgcac caccaactgc ttag

<210> 25
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
primer

<400> 25
gcctgcttca ccaccttctt gatg

<210> 26
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
primer

<400> 26
gccagcacat agagagaatg agc

<210> 27
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
primer

<400> 27
caaggctcac agtgattttc tgg

<210> 28

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
peptide

<400> 28

Ala Cys Arg Gly Asp Met Phe Gly Cys Ala
1 5 10

<210> 29

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 29

aagctgaccc tgaagttcat c

<210> 30

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
oligonucleotide

<400> 30

aagcagcacg acttcttcaa g

<210> 31

<211> 21

<212> DNA

<213> Homo sapiens

<400> 31

aagtgggtccc aggctgcacc c

<210> 32

<211> 21

<212> DNA

<213> Homo sapiens

<400> 32

aagatccgca gacgtgtaaa t

<210> 33
<211> 21
<212> DNA
<213> Homo sapiens

<400> 33
aaacacagac tcgcgttgca a

<210> 34
<211> 21
<212> DNA
<213> Homo sapiens

<400> 34
aacacagact cgcgttgcaa g

<210> 35
<211> 21
<212> DNA
<213> Homo sapiens

<400> 35
aaggcgaggc agcttgagtt a

<210> 36
<211> 21
<212> DNA
<213> Homo sapiens

<400> 36
aaacgaacgt acttgacagat g

<210> 37
<211> 21
<212> DNA
<213> Homo sapiens

<400> 37
aacgaacgta cttgcagatg t

<210> 38
<211> 21
<212> DNA
<213> Homo sapiens

<400> 38
aacgtacttg cagatgtgac a

<210> 39

<211> 21
<212> DNA
<213> Homo sapiens

<400> 39
aatcgagacc ctggtggaca t

<210> 40
<211> 21
<212> DNA
<213> Homo sapiens

<400> 40
aaggccagca cataggagag a

<210> 41
<211> 21
<212> DNA
<213> Homo sapiens

<400> 41
aaggaggagg gcagaatcat c

<210> 42
<211> 21
<212> DNA
<213> Homo sapiens

<400> 42
aatgcagacc aaagaaagat a

<210> 43
<211> 21
<212> DNA
<213> Homo sapiens

<400> 43
aatgtgaatg cagaccaaag a

<210> 44
<211> 21
<212> DNA
<213> Homo sapiens

<400> 44
aacatcacca tgcagattat g

<210> 45
<211> 21
<212> DNA
<213> Homo sapiens



<400> 45
aagcatttgt ttgtacaaga t

<210> 46
<211> 21
<212> DNA
<213> Homo sapiens

<400> 46
aagtgggtgaa gttcatggat g

<210> 47
<211> 21
<212> DNA
<213> Homo sapiens

<400> 47
aagatagagc aagacaagaa a

<210> 48
<211> 21
<212> DNA
<213> Homo sapiens

<400> 48
aatccctgtg ggccttgctc a

<210> 49
<211> 21
<212> DNA
<213> Homo sapiens

<400> 49
aaatgtgaat gcagaccaaa g

<210> 50
<211> 21
<212> DNA
<213> Homo sapiens

<400> 50
aatgacgagg gcctggagtg t

<210> 51
<211> 21
<212> DNA
<213> Homo sapiens

<400> 51
aaagtgggtg catggataga t

<210> 52
<211> 21
<212> DNA
<213> Homo sapiens

<400> 52
aagtgggtgtc atggatagat g

<210> 53
<211> 21
<212> DNA
<213> Homo sapiens

<400> 53
aaacagctgg tgcccagctg c

<210> 54
<211> 21
<212> DNA
<213> Homo sapiens

<400> 54
aagtcggat gcagatcctc a

<210> 55
<211> 21
<212> DNA
<213> Homo sapiens

<400> 55
aagaacacag ccagtgtgaa t

<210> 56
<211> 21
<212> DNA
<213> Homo sapiens

<400> 56
aacacagcca gtgtgaatgc a

<210> 57
<211> 21
<212> DNA
<213> Homo sapiens

<400> 57
aaaggacagt gctgtgaagc c

<210> 58

<211> 21
<212> DNA
<213> Homo sapiens

<400> 58
aaggacagtg ctgtgaagcc a

<210> 59
<211> 21
<212> DNA
<213> Homo sapiens

<400> 59
aagccagaca gggctgccac t

<210> 60
<211> 21
<212> DNA
<213> Homo sapiens

<400> 60
aaccagaca cctgcaggtg c

<210> 61
<211> 21
<212> DNA
<213> Homo sapiens

<400> 61
aaggagagga cctgaaactg t

<210> 62
<211> 21
<212> DNA
<213> Homo sapiens

<400> 62
aagcaaggag ggcctctgat g

<210> 63
<211> 21
<212> DNA
<213> Homo sapiens

<400> 63
aaggagggcc tctgatggtg a

<210> 64
<211> 21
<212> DNA
<213> Homo sapiens

<400> 64

aactacctca agagcaaacg t

<210> 65

<211> 21

<212> DNA

<213> Homo sapiens

<400> 65

aagtggccag aggcatggag t

<210> 66

<211> 21

<212> DNA

<213> Homo sapiens

<400> 66

aaagtgcatt catcgggacc t

<210> 67

<211> 21

<212> DNA

<213> Homo sapiens

<400> 67

aagtgcattc atcgggacct g

<210> 68

<211> 21

<212> DNA

<213> Homo sapiens

<400> 68

agcacgctgt ttattgaaag a

<210> 69

<211> 21

<212> DNA

<213> Homo sapiens

<400> 69

aagggttca tcatatcaaa t

<210> 70

<211> 21

<212> DNA

<213> Homo sapiens

<400> 70

aaaggctgag cataactaaa t



<210> 71
<211> 21
<212> DNA
<213> Homo sapiens

<400> 71
aaggtcttct tctgaaataa a

<210> 72
<211> 21
<212> DNA
<213> Homo sapiens

<400> 72
aatgccatac tgacaggaaa t

<210> 73
<211> 21
<212> DNA
<213> Homo sapiens

<400> 73
aagaggatgc agggaattat a

<210> 74
<211> 21
<212> DNA
<213> Homo sapiens

<400> 74
aaggcgacga attgaccaaa g

<210> 75
<211> 21
<212> DNA
<213> Homo sapiens

<400> 75
aagatcctga actgagttta a

<210> 76
<211> 21
<212> DNA
<213> Homo sapiens

<400> 76
aaggctgagc ataactaaat c

<210> 77

<211> 21
<212> DNA
<213> Homo sapiens

<400> 77
aaggccaaga ttgcagaac t

<210> 78
<211> 21
<212> DNA
<213> Homo sapiens

<400> 78
aacacctcag tgcatatata t

<210> 79
<211> 21
<212> DNA
<213> Homo sapiens

<400> 79
aaagggttc atcatatcaa a

<210> 80
<211> 21
<212> DNA
<213> Homo sapiens

<400> 80
aatcctccag aagaaagaaa t

<210> 81
<211> 21
<212> DNA
<213> Homo sapiens

<400> 81
aacagaattt cctgggacag c

<210> 82
<211> 21
<212> DNA
<213> Homo sapiens

<400> 82
aactgaagac aggctacttg t

<210> 83
<211> 21
<212> DNA
<213> Homo sapiens

<400> 83
aaggacttcc tgaccttgga g

<210> 84
<211> 21
<212> DNA
<213> Homo sapiens

<400> 84
aagtggctaa gggcatggag t

<210> 85
<211> 21
<212> DNA
<213> Homo sapiens

<400> 85
aagggcatgg agttcttggc a

<210> 86
<211> 21
<212> DNA
<213> Homo sapiens

<400> 86
aaatgtacca gaccatgctg g

<210> 87
<211> 21
<212> DNA
<213> Homo sapiens

<400> 87
aattccatta tgacaacaca g

<210> 88
<211> 21
<212> DNA
<213> Homo sapiens

<400> 88
aacagtaagc gaaagagccg g

<210> 89
<211> 21
<212> DNA
<213> Homo sapiens

<400> 89
atgacaacac agcaggaatc a



<210> 90
<211> 21
<212> DNA
<213> Homo sapiens

<400> 90
aagctcagca cacagaaaga c

<210> 91
<211> 21
<212> DNA
<213> Homo sapiens

<400> 91
aatgcggcgg tggcgacagt a

<210> 92
<211> 21
<212> DNA
<213> Homo sapiens

<400> 92
aatgccacca tggtctctaa t

<210> 93
<211> 21
<212> DNA
<213> Homo sapiens

<400> 93
aagctcctga agatctgtat a

<210> 94
<211> 21
<212> DNA
<213> Homo sapiens

<400> 94
aagcagatgc ctttggaatt g

<210> 95
<211> 21
<212> DNA
<213> Homo sapiens

<400> 95
aagcggctac cagtccggat a

<210> 96

<211> 21
<212> DNA
<213> Homo sapiens

<400> 96
aagtcctca gtgatgtaga a

<210> 97
<211> 21
<212> DNA
<213> Homo sapiens

<400> 97
aagtgttct accgggaaac t

<210> 98
<211> 21
<212> DNA
<213> Homo sapiens

<400> 98
aatccctgtg gatctgaaac g

<210> 99
<211> 21
<212> DNA
<213> Homo sapiens

<400> 99
aaggctaata caactcttca a

<210> 100
<211> 21
<212> DNA
<213> Homo sapiens

<400> 100
aatcccattht caaaggagaa g

<210> 101
<211> 21
<212> DNA
<213> Homo sapiens

<400> 101
aagtgatag agagagctaa t

<210> 102
<211> 21
<212> DNA
<213> Homo sapiens

<400> 102
aaggctgctg gattccagta t

<210> 103
<211> 21
<212> DNA
<213> Homo sapiens

<400> 103
aagcagtctg tgattgaaat g

<210> 104
<211> 21
<212> DNA
<213> Homo sapiens

<400> 104
aagccctcat cactggttgt g

<210> 105
<211> 21
<212> DNA
<213> Homo sapiens

<400> 105
aaaggacatg gttagaatta a

<210> 106
<211> 21
<212> DNA
<213> Homo sapiens

<400> 106
aaggccttgg ccgtctggtt a

<210> 107
<211> 21
<212> DNA
<213> Homo sapiens

<400> 107
aagggtgtca ggtatttctt a

<210> 108
<211> 21
<212> DNA
<213> Homo sapiens

<400> 108
aatggagcga agctttcata t



<210> 109
<211> 21
<212> DNA
<213> Homo sapiens

<400> 109
aagtactgtg aagatgttaa t

<210> 110
<211> 21
<212> DNA
<213> Homo sapiens

<400> 110
aaggacatgg ttagaattaa c

<210> 111
<211> 21
<212> DNA
<213> Homo sapiens

<400> 111
aaggtactct cgcaggaaat g

<210> 112
<211> 21
<212> DNA
<213> Homo sapiens

<400> 112
aaacggaggc tgtgaacata t

<210> 113
<211> 21
<212> DNA
<213> Homo sapiens